Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment
18/01/2022 12:24
Jan 18 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX ANNOUNCES COMMENCEMENT OF PATIENT ENROLLMENT
AND
DOSING IN A PHASE 2B TRIAL FOR A PROMISING CANADIAN-DEVELOPED
COVID-19 TREATMENT
Source text for Eikon: ID:nGNX7M8VzV
Further company coverage: RVX.TO
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment